Cost-utility analysis of the wearable cardioverter defibrillator in high-risk post-myocardial infarction patients in the Spanish healthcare system - Summary - MDSpire
Advertisement
Cost-utility analysis of the wearable cardioverter defibrillator in high-risk post-myocardial infarction patients in the Spanish healthcare system
To assess the cost-utility of the wearable cardioverter defibrillator (WCD) in combination with guideline-directed medical therapy (GDMT) compared with GDMT alone in post-MI patients with reduced left ventricular ejection fraction at increased risk of sudden cardiac death.
Key Findings:
WCD plus GDMT was associated with projected gains of 0.53 life years and 0.43 quality-adjusted life years (QALYs) compared to GDMT alone.
Total lifetime costs were €113,290 for WCD plus GDMT versus €102,032 for GDMT alone.
The incremental cost-effectiveness ratio was €26,145 per QALY gained, below the €30,000 threshold.
The probability of cost-effectiveness for patients during the early post-MI period was 78.3%.
Interpretation:
In Spain, temporary WCD use alongside GDMT after MI shows potential to improve health outcomes at an incremental cost that falls within commonly cited willingness-to-pay thresholds.
Limitations:
The analysis is based on a hypothetical cohort and may not fully capture real-world variability.
Transferability of international economic evidence is limited by differences in clinical practice patterns and resource use.
Conclusion:
These findings support the adoption of WCD therapy for patients at transiently high risk of sudden cardiac death, emphasizing the importance of appropriate patient selection and adherence in clinical practice.
